Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 33

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 33
---
                                                
 property and proprietary protection for our products and technologies and to avoid claims of infringement, misappropriation or other violation 
 of third-party intellectual property and proprietary rights;                                                                                   |

| · | the outcome of any current or future litigation; |

| · | our ability to hire and retain key management; |

| · | our ability to obtain additional financing; |

| · | our beliefs and objectives for future operations; |

| · | our ability to maintain, protect, and enhance our intellectual property; |

| · | our expectations concerning relationships with third parties, including strategic partners; |

| · | the volatility of the trading price of our common stock; |

| · | evolving regulations and the potential for unfavorable changes to, or failure by us to comply with, regulations; 
 and                                                                                                              |

| · | our expectations regarding the period during which we qualify as an emerging growth company under the 
 Jumpstart Our Business Act.                                                                           |

The forward-looking statements
contained in this prospectus reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise
from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume
no responsibility for updating any forward-looking statements.

We qualify all of our
forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim
the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

<div align='center'>6

USE OF PROCEEDS</div>

We cannot assure you that we will receive any
proceeds in connection with securities that may be offered pursuant to this prospectus. Unless otherwise indicated in the applicable prospectus
supplement, we may use any net proceeds from the sale of securities under this prospectus for general corporate purposes, including working
capital, research and development, payments for research and development — licenses acquired, sales and marketing
activities, general administrative matters, operating expenses and capital expenditures. As a result, our management will have broad discretion
to allocate the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus for any purpose. Pending
application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade, interest-bearing
securities or apply them to the reduction of short-term indebtedness.

<div align='center'>7

DESCRIPTION OF CAPITAL STOCK</